Stephanie Davis
Stock Analyst at Barclays
(0.57)
# 4,143
Out of 5,140 analysts
95
Total ratings
31.34%
Success rate
-108.84%
Average return
Main Sectors:
Stocks Rated by Stephanie Davis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DGX Quest Diagnostics | Maintains: Overweight | $210 → $225 | $202.41 | +11.16% | 8 | Feb 11, 2026 | |
| WAY Waystar Holding | Maintains: Overweight | $50 → $45 | $25.07 | +79.50% | 6 | Apr 14, 2025 | |
| OPRX OptimizeRx | Maintains: Equal-Weight | $11 → $5 | $8.20 | -39.02% | 3 | Nov 14, 2024 | |
| DOCS Doximity | Maintains: Overweight | $52 → $75 | $25.55 | +193.54% | 5 | Nov 11, 2024 | |
| LFST LifeStance Health Group | Maintains: Underweight | $6 → $7 | $7.15 | -2.10% | 2 | Nov 11, 2024 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $10 → $6 | $2.47 | +142.91% | 7 | Nov 11, 2024 | |
| EVH Evolent Health | Maintains: Overweight | $39 → $19 | $2.79 | +581.00% | 1 | Nov 11, 2024 | |
| COR Cencora | Maintains: Overweight | $263 → $290 | $361.08 | -19.69% | 2 | Nov 7, 2024 | |
| CAH Cardinal Health | Maintains: Overweight | $117 → $133 | $224.44 | -40.74% | 2 | Nov 4, 2024 | |
| OMCL Omnicell | Maintains: Equal-Weight | $39 → $58 | $40.26 | +44.06% | 2 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $3 | $4.99 | -39.88% | 7 | Oct 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $213 → $249 | $282.67 | -11.91% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $29 | $12.71 | +128.17% | 11 | Jan 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $4.74 | +617.30% | 9 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $59 → $34 | $20.98 | +62.06% | 3 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $242 → $233 | $180.31 | +29.22% | 9 | Dec 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $17 | $1.79 | +849.72% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $76 | $78.90 | -3.67% | 5 | Jun 7, 2022 |
Quest Diagnostics
Feb 11, 2026
Maintains: Overweight
Price Target: $210 → $225
Current: $202.41
Upside: +11.16%
Waystar Holding
Apr 14, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $25.07
Upside: +79.50%
OptimizeRx
Nov 14, 2024
Maintains: Equal-Weight
Price Target: $11 → $5
Current: $8.20
Upside: -39.02%
Doximity
Nov 11, 2024
Maintains: Overweight
Price Target: $52 → $75
Current: $25.55
Upside: +193.54%
LifeStance Health Group
Nov 11, 2024
Maintains: Underweight
Price Target: $6 → $7
Current: $7.15
Upside: -2.10%
GoodRx Holdings
Nov 11, 2024
Maintains: Overweight
Price Target: $10 → $6
Current: $2.47
Upside: +142.91%
Evolent Health
Nov 11, 2024
Maintains: Overweight
Price Target: $39 → $19
Current: $2.79
Upside: +581.00%
Cencora
Nov 7, 2024
Maintains: Overweight
Price Target: $263 → $290
Current: $361.08
Upside: -19.69%
Cardinal Health
Nov 4, 2024
Maintains: Overweight
Price Target: $117 → $133
Current: $224.44
Upside: -40.74%
Omnicell
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $39 → $58
Current: $40.26
Upside: +44.06%
Oct 29, 2024
Maintains: Equal-Weight
Price Target: $2 → $3
Current: $4.99
Upside: -39.88%
Aug 2, 2024
Maintains: Equal-Weight
Price Target: $213 → $249
Current: $282.67
Upside: -11.91%
Jan 3, 2024
Initiates: Overweight
Price Target: $29
Current: $12.71
Upside: +128.17%
Feb 23, 2023
Upgrades: Outperform
Price Target: $34
Current: $4.74
Upside: +617.30%
Jan 5, 2023
Downgrades: Market Perform
Price Target: $59 → $34
Current: $20.98
Upside: +62.06%
Dec 2, 2022
Maintains: Outperform
Price Target: $242 → $233
Current: $180.31
Upside: +29.22%
Nov 9, 2022
Maintains: Outperform
Price Target: $20 → $17
Current: $1.79
Upside: +849.72%
Jun 7, 2022
Maintains: Outperform
Price Target: $67 → $76
Current: $78.90
Upside: -3.67%